SCHEMBL615404

SCHEMBL615404

Cc1nc2c(Cl)c(N(S(=O)(=O)c3cccc(Cl)c3C)S(=O)(=O)c3cccc(Cl)c3C)ccc2s1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 7/20 0.43
SLC40A1 Q9NP59 1/20 0.37
PKLR P30613 1/20 0.36
EDNRB P24530 2/20 0.34
EDNRA P25101 2/20 0.34
PKM P14618 1/20 0.33
HSD17B1 P14061 1/20 0.33
HSD17B2 P37059 1/20 0.33
CCR4 P51679 1/20 0.33
MAPT P10636 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
KDM4E B2RXH2 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10089793 0.95 HSD11B1 (0.40) HSD11B1SLC40A1PKLREDNRBEDNRA
SCHEMBL618696 0.78 GAA (0.41) HSD11B1PKLRPKMMAPTKDM4E
SCHEMBL616832 0.77 HSD11B1 (0.69) HSD11B1SLC40A1PKLREDNRBEDNRA
SCHEMBL617340 0.74 LMNA (0.43) PKLRPKMMAPTKDM4E
SCHEMBL617902 0.73 HSD11B1 (0.52) HSD11B1SLC40A1PKLREDNRBEDNRA
SCHEMBL616245 0.73 CNR2 (0.38) HSD11B1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL10089789 0.72 HSD11B1 (0.51) HSD11B1SLC40A1PKLREDNRBEDNRA
SCHEMBL10089753 0.71 ALDH1A1 (0.61) PKMMAPTMCOLN3KDM4E
SCHEMBL617793 0.70 TP53 (0.47) PKMMAPT
SCHEMBL10089740 0.69 ALDH1A1 (0.47) HSD11B1PKMHSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
EP-1556040-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 Sterix Limited (GB) 2005-07-27 EP disclosed
US-20040143124-A1 Compound STERIX LIMITED (GB) 2004-07-22 US disclosed
WO-2004037251-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 STERIX LIMITED (GB) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer HSD11B1, HSD3B1, HSD11B2 HSD11B1 1/4885SLC40A1 4441/4885PKLR 978/4885
US-20110009448-A1 Compound NR4A1, GPR6, PRMT6 HSD11B1 331/4885SLC40A1 3111/4885PKLR 2009/4885
US-20120041207-A1 Compound NR4A1, GPR6, PRMT6 HSD11B1 331/4885SLC40A1 3111/4885PKLR 2009/4885
US-20040143124-A1 Compound NR4A1, CBR1, NR2C2 HSD11B1 192/4885SLC40A1 2902/4885PKLR 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.